Table 1.
Patient characteristics
| Parameter | Study treatment | ||
|---|---|---|---|
| Control (n = 16) | SrRan (n = 16) | SrRan + AD3 (n = 16) | |
| Age (years, mean ± SD) | 62.9 ± 1.52 | 63.3 ± 1.50 | 61.1 ± 1.35 |
| Median (IQR) | 62.5 (58.8–65.3) | 62.5 (59.8–65.8) | 59.5 (58.8–62.0) |
| BMI (kg/m2, mean ± SD) | 31.2 ± 1.14 | 30.4 ± 1.06 | 32.7 ± 0.50 |
| Median (IQR) | 30.0 (28.5–33.4) | 29.2 (28.1–32.4) | 32.0 (30.8–34.5) |
| Menopause age (years, mean ± SD) | 50.5 ± 0.89 | 49.8 ± 0.77 | 46.8 ± 1.36 |
| Median (IQR) | 50.0 (47.8–53.0) | 50.0 (47.8–50.8) | 45.5 (44.3–50.8) |
| Menopause duration (years, mean ± SD) | 12.4 ± 1.08 | 13.5 ± 1.23 | 14.4 ± 2.11 |
| Median (IQR) | 12.0 (10.0–13.5) | 13.0 (10.8–16.0) | 12.0 (9.8–17.0) |
| Fracture history [n (%)] | |||
| Hip | 1 (6.3) | 0 (0) | 1 (6.3) |
| Wrist | 1 (6.3) | 3 (18.8) | 0 (0) |
| Spine | 0 (0) | 0 (0) | 1 (6.3) |
| Family history of fractures [n (%)] | 2 (12.5) | 4 (25.0) | 3 (18.8) |
| Menopause before 45 years [n (%)] | 1 (6.3) | 1 (6.3) | 3 (18.8) |
AD 3 alfacalcidol, BMI body mass index, IQR interquartile range (25th–75th percentiles), SD standard deviation, SrRan strontium ranelate